RTTNews | Sep 27, 2021 05:03PM EDT

17:02 Monday, September 27, 2021 (RTTNews.com) - Biopharmaceutical company Altimmune, Inc. (ALT) on Monday announced that the company will report results from a Phase 1 clinical trial of ALT-801 in overweight and obese subjects.

The company said it will discuss the results in a pre-market press release, conference call and webcast on September 28 at 8:30 a.m. ET.

Altimmune said it is focused on developing treatments for obesity and liver diseases.

ALT closed Monday's trading at $15.19, up $0.22 or 1.47%, on the NYSE. The stock further gained $0.60 or 3.95% in the after-hours trade.

Read the original article on RTTNews ( https://www.rttnews.com/3228492/altimmune-to-report-results-of-obesity-treatment-on-sept-28.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved